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ABSTRACT
The mTORC1 inhibitors, rapamycin and its analogs, are known to show only 
modest antitumor activity in clinic, but the underlying mechanisms remain largely 
elusive. Here, we found that activated AKT signaling is associated with rapamycin 
resistance in breast and colon cancers by sustained phosphorylation of the 
translational repressor 4E-BP1. Treatment of tumor cells with rapamycin or the AKT 
inhibitor MK2206 showed a limited activity in inhibiting 4E-BP1 phosphorylation, 
cap-dependent translation, cell growth and motility. However, treatment with both 
drugs resulted in profound effects in vitro and in vivo. Mechanistic investigation 
demonstrated that the combination treatment was required to effectively inhibit 
PRAS40 phosphorylation on both Ser183 and Thr246 mediated by mTORC1 and AKT 
respectively, and with the combined treatment, dephosphorylated PRAS40 binding to 
the raptor/mTOR complex was enhanced, leading to dramatic repression of mTORC1-
regulated 4E-BP1 phosphorylation and translation. Knockdown of PRAS40 or 4E-
BP1 expression markedly reduced the dependence of tumor cells on AKT/mTORC1 
signaling for translation and survival. Together, these findings reveal a critical role 
of PRAS40 as an integrator of mTORC1 and AKT signaling for 4E-BP1-mediated 
translational regulation of tumor cell growth and motility, and highlight PRAS40 
phosphorylation as a potential biomarker to evaluate the therapeutic response to 
mTOR/AKT inhibitors.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K)/AKT 
signaling pathway is frequently deregulated in a majority 
of human cancers [1]. This pathway is activated by 
mutations in genes that encode multiple components of 
the pathway or upstream activation of receptor tyrosine 
kinases [2]. Activation of PI3K/AKT signaling pathway 
has long been shown to be necessary for key features of 
the transformed phenotype, suggesting that inhibition of 
the pathway could be a useful therapeutic strategy [3]. 
The mammalian target of rapamycin (mTOR) protein 
kinase is a major component of the PI3K/AKT pathway, 
which controls cell growth, proliferation, survival and 
metabolism by integrating a variety of signals from growth 
factors and nutrients [4]. mTOR exerts its biological 
functions by the formation of two distinct protein 
complexes: the mTOR complex 1 (mTORC1) and the 
mTOR complex 2 (mTORC2). mTORC1 is composed of 
mTOR, raptor, mLST8, deptor and the proline-rich AKT 
substrate of 40 kilodaltons (PRAS40). To date, protein 
synthesis is the best-characterized process controlled 
by mTORC1 [4]. mTORC1 directly phosphorylates the 
eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1 (4E-BP1) on Thr37 and Thr46 which act as 
priming sites for its subsequent phosphorylation on Ser65 
and Thr70 [5]. The phosphorylation of 4E-BP1 prevents 
its binding to the cap-binding protein eIF4E, which 
allows eIF4E to participate in the assembly of the eIF4F 
translation initiation complex, a rate-limiting step for the 
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cap-dependent mRNA translation and protein synthesis 
[6]. We and others have shown that inhibition of mTORC1 
downregulates a number of certain key oncogenic mRNAs 
encoding proteins involved in cell-cycle progression, cell 
survival, angiogenesis and metastasis [7-10], and that 
dephosphorylated 4E-BP1 is an important biomarker for 
predicting a response to AKT/mTOR inhibitors [9-14].
PRAS40, first reported as substrate for AKT 
[15], is an inhibitory component of mTORC1 [16, 17]. 
Upon activation, mTORC1 can phosphorylate PRAS40 
on Ser183 [18], which is in addition to the AKT-
phosphorylated PRAS40 on Thr246 [15]. Phosphorylation 
of PRAS40 by AKT and mTORC1 results in disassociation 
of PRAS40 from mTORC1 and relieves its inhibitory 
constraint on mTORC1 activity [16-18]. Recent studies 
have shown that increased phosphorylation of PRAS40 is 
associated with malignant progression and poor prognosis 
in patients [19-21]. 
Rapamycin and its analogs (rapalogs) are allosteric 
inhibitors of mTORC1 via their binding to FKBP12, and 
were among the first mTOR-targeted therapeutics to enter 
the clinic [22]. However, patients whose tumors harbor a 
mutational activation of PI3K/AKT signaling, such as in 
breast, colon and prostate cancer and glioblastoma, exhibit 
a low response rate with rapalogs [22, 23]. It is widely 
believed that this inadequate therapeutic response may 
result from incomplete inhibition of mTORC1-mediated 
phosphorylation of 4E-BP1 and a concomitant activation 
of AKT via loss of a negative feedback mechanism [4, 
22, 24, 25]. However, the molecular basis of incomplete 
inhibition of 4E-BP1 phosphorylation by rapamycin and 
how activated AKT signaling contributes to rapalogs 
resistance remain largely unknown. 
In the present study, we demonstrate that the 
redundant phosphorylation of PRAS40 by both AKT 
and mTORC1 signaling is a novel mechanistic basis 
for the acquired resistance to rapamycin in cancer cells. 
Combined inhibition of AKT and mTORC1 is required 
for effective inhibition of PRAS40 phosphorylation on 
both Ser183 and Thr246 sites, which in turn increases 
the ability of PRAS40 to inhibit mTORC1-mediated 4E-
BP1 phosphorylation and translation concomitant with 
suppression of tumor growth and cell motility. Our data 
uncover an important role of PRAS40 in the translational 
control of tumor progression and therapeutic response to 
mTORC1 inhibitors.
RESULTS
AKT inhibition profoundly enhances the 
inhibitory effect of rapamycin on cap-dependent 
translation by dephosphorylation of 4E-BP1
We and others have previously shown that the 
phosphorylation status of 4E-BP1 and its regulated cap-
dependent translation activity are linked with cancer 
progression and therapeutic responses in tumors such as in 
breast and colon cancers with mutational activation of the 
PI3K/AKT signaling pathway [9-13, 26-29]. To determine 
whether the deregulated cap-dependent translation and 
feedback activation of AKT contribute to rapamycin 
resistance, we first examined the effects of rapamycin and 
the AKT inhibitor MK2206, alone and in combination, 
on 4E-BP1-regulated cap-dependent translation activity. 
In a panel of breast (MCF7, BT474, MDA-MB-453) and 
colon (HCT116) cancer cell lines, all with mutations in 
the gene that encodes the catalytic subunit of PI3K p110α 
(PIK3CA), rapamycin at 50 nM effectively inhibited 
phosphorylation of the mTORC1 substrate p70S6 kinase 
(p70S6K) and its downstream target S6 (Figure 1A). 
Nonetheless, rapamycin induced feedback activation of 
AKT, as indicated by phosphorylation on both Ser473 
and Thr308 of AKT, and showed only weak inhibition 
on the phosphorylation of 4E-BP1 at its four mTORC1-
regulated phosphorylation sites (Thr37, Thr46, Ser65, 
Thr70). MK2206 is a highly selective, allosteric inhibitor 
of AKT1, 2, and 3 that inhibits the phosphorylation of 
these kinases by preventing their association with the 
membrane [26, 30]. Treatment with MK2206 at 1 µM 
effectively inhibited AKT phosphorylation on both Ser473 
and Thr308, but similar to rapamycin, had only a marginal 
effect on 4E-BP1 phosphorylation. However, MK2206 
blunted the feedback activation of AKT by rapamycin and 
profoundly blocked phosphorylation of 4E-BP1 at all four 
of its phosphorylation sites in the four PIK3CA mutant cell 
lines (Figure 1A). Dephosphorylation of 4E-BP1 allows 
it to bind to the eIF4E-mRNA cap complex and prevents 
cap-dependent translation [6]. In MCF7 and HCT116 
cells, treatment with either rapamycin or MK2206 
slightly induced 4E-BP1 binding to the eIF4E-mRNA cap 
complex. However, the combination of both drugs caused 
marked recruitment of 4E-BP1 to the mRNA cap-complex 
(Figure 1B). As a result, cap-dependent translation was 
inhibited markedly by combination of rapamycin and 
MK2206 compared with either agent alone in all the four 
tested cancer cell lines (Figure 1C). These results suggest 
that in tumor cells with mutational activation of PI3K/
AKT signaling pathway, combined inhibition of both AKT 
and mTORC1 signaling is required to effectively inhibit 
phosphorylation of 4E-BP1, which in turn, represses cap-
dependent translation.
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4E-BP1 mediates the effects of AKT and 
mTORC1 signaling on cell proliferation, survival 
and motility
To examine the functional consequences of 
mTORC1 and AKT cooperation on 4E-BP1-regulated 
translation, the effects of rapamycin and MK2206, 
alone and in combination, on cell proliferation were 
first determined. As shown in Figure 2A, simultaneous 
administration of MK2206 and rapamycin to MCF7, 
BT474, MDA-MB-453 and HCT116 cells for 72 h 
resulted in a marked inhibitory effect on cell proliferation 
compared with either agent alone. Cell cycle analysis 
revealed a dramatic increase of G1 phase in the MCF7 
and BT474 cell lines after 24 h of treatment with the 
combination of AKT and mTORC1 inhibitors when 
compared with cells treated with either agent alone or with 
DMSO as control (Figure 2B and Supplementary Figure 
1A). Apoptosis was assessed by staining cells with the 
apoptotic marker annexin V followed by FACS analysis. 
In BT474 and MCF7 cells, rapamycin or MK2206 
alone had little or modest increase (3%-7% in MCF7 
and 10%-27% in BT474) in induction of apoptosis as 
compared with control at 72 h after drug exposure, but the 
combination induced a marked induction (30% and 46% 
Figure 1: AKT inhibition profoundly enhances the inhibitory effects of rapamycin on 4E-BP1 phosphorylation and 
cap-dependent translation in breast and colon cancer cells. A. The indicated cells were treated with 50 nM rapamycin (Rap) and 
1 µM MK2206, alone or in combination, or DMSO as control for 12 h. Cell lysates were subjected to Western blot analysis for the indicated 
proteins. B. MCF7 and HCT116 cell lysates from (A) were precipitated with m7GTP sepharose beads followed by Western blot analysis for 
the indicated proteins. C. The indicated cells were transfected with a bicistronic luciferase reporter that detects cap-dependent translation 
of the Renilla luciferase gene and cap-independent poliovirus IRES-mediated translation of the firefly luciferase gene. The transfected cells 
were treated with the drugs as indicated in (A) for 12 h. The cap-dependent translation activity was determined as described in the Material 
and Methods. The results are expressed as the inhibition of cap-dependent translation relative to the DMSO-treated controls and presented 
as means ± S.E.M. (n = 3). *P < 0.05 for combination of Rap and MK2206 versus Rap or MK2206.
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Figure 2: 4E-BP1 integrates the effects of AKT and mTORC1 signaling on cell proliferation and survival. A. The growth 
of the indicated cells was assessed after 3 days of treatment with 50 nM rapamycin (Rap) and 1 µM MK2206, alone or in combination 
or DMSO as control (Ctrl). The results are shown as a percentage of cell number relative to DMSO-treated control cells. *P < 0.03 for 
combination of Rap and MK2206 versus DMSO Ctrl, Rap or MK2206. B, C. Cell cycle distribution (B) and induction of apoptosis (C) in 
MCF7 and BT474 cells treated with 50 nM rapamycin (Rap) and 1 µM MK2206, alone or in combination or DMSO as control for 24 h 
(B) and 72 h (C), respectively, were analyzed by flow cytometry. The results are expressed as the increased levels of G1 (B) and apoptosis 
(C) by subtracting each of the DMSO-treated controls. #P < 0.02 for combination of Rap and MK2206 versus Rap or MK2206. D. BT474 
and MDA-MB-453 cells were treated with the drugs as indicated in Figure 1a for 12 h followed by Western blot analysis for the indicated 
proteins. E. Inhibition of cap-dependent translation activity by the indicated drugs in MCF7 and HCT116 cells with stable expression 
of control shRNA or 4E-BP1 shRNA was determined and analyzed as in Figure 1C. F, G. The increased levels of G1 (F) and apoptosis 
(G) by the indicated drugs in MCF7 cells with stable expression of control shRNA or 4E-BP1 shRNA were determined as in (B) and 
(C), respectively. **P < 0.02 for combination of Rap and MK2206 in Sh 4E-BP1 cells versus that in Sh Ctrl cells. Data shown in graphs 
represent the mean ± S.E.M. (n = 3).
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in MCF7 and BT474, respectively) of apoptosis (Figure 
2C and Supplementary Figure 1B). Western blot analysis 
further showed that combination treatment with rapamycin 
and MK2206 was more effective than either agent alone 
in downregulating D-cyclin expression, activation of 
caspase-3 and/or caspase-7, key effectors of apoptosis, and 
increasing levels of cleaved PARP, a caspase substrate, in 
BT474 and MDA-MB-453 cells (Figure 2D). Collectively, 
these data demonstrate that AKT inhibition sensitizes 
tumor cells to rapamycin by enhancing G1 arrest and 
induction of apoptosis.
To determine whether 4E-BP1-regulated translation 
is directly involved in the anti-proliferative and apoptotic 
responses to combined inhibition of AKT and mTORC1 
signaling, 4E-BP1 gene was knocked down in HCT116 
and MCF7 cells (Supplementary Figure 2) using a specific 
shRNA target sequence as we have verified previously [9]. 
Combined treatment with rapamycin and MK2206 caused 
a 35% and 40% inhibition of cap-dependent translation 
in HCT116 and MCF7 control cells respectively, but had 
much less effect in 4E-BP1 knockdown HCT116 (12%) 
or MCF7 (22%) cells (Figure 2E). Furthermore, silencing 
Figure 3: The effects of AKT and mTORC1 activation on cell migration and invasion are mediated by 4E-BP1. A, B. 
Transwell migration A. and invasion B. analyses of MCF7 and HCT116 cells were performed in the presence of 50 nM rapamycin (Rap) 
and 1 µM MK2206, alone or in combination, or DMSO as control for 6 h (A) and 30 h (B), respectively. The results represent the mean 
number of migrated (A) or invaded (B) cells per field ± S.E.M. (n = 3). *P < 0.03 for combination of Rap and MK2206 versus DMSO Ctrl, 
Rap or MK2206. C. Migration analysis of HCT116 cells with stable expression of control shRNA or 4E-BP1 shRNA was performed in 
the presence of the drugs as indicated in (A) for 6 h. The results are expressed as the inhibition of migration relative to the DMSO-treated 
controls. **P < 0.02 for combination of Rap and MK2206 in Sh 4E-BP1 cells versus that in Sh Ctrl cells. Data shown in graphs represent 
the mean ± S.E.M. (n = 3).
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4E-BP1 expression in MCF7 and BT474 cells markedly 
reversed the inhibitory effects of the combination on 
G1 arrest and induction of apoptosis (Figure 2F, 2G and 
Supplementary Figures 2 and 3).
Our recent studies show that 4E-BP1-regulated 
cap-dependent translation also plays an important role 
in controlling cancer cell motility and metastasis [9, 
10]. Using Boyden chamber assays described previously 
[9], treatment with rapamycin or MK2206 alone for 6 
h had only a modest effect on MCF7 and HCT116 cell 
migration. However, a combination of both drugs was 
effective in inhibiting their migration (Figure 3A). Similar 
results were observed in the ability of HCT116 cells that 
invade through Matrigel 30 h after drug exposure (Figure 
3B). Notably, knockdown of 4E-BP1 expression in 
HCT116 cells profoundly reduced the inhibitory effect of 
combined treatment on cell migration compared with that 
in the control cells (Figure 3C). 
Taken together, these data suggest that AKT and 
mTORC1 signaling co-regulate 4E-BP1 phosphorylation, 
Figure 4: Combined inhibition of AKT and mTORC1 is required for effective inhibition of PRAS40 phosphorylation 
on both S183 and T246 and induction of PRAS40-repressive function on mTORC1. A. Cells were treated with the drugs 
as indicated in Figure 1A for 12 h followed by Western blot analysis for the indicated proteins. B. HCT116 cell lysates from A. were 
immunoprecipitated with the mouse PRAS40 antibody or control IgG followed by Western blot analysis for the indicated proteins. C. 
MCF7 and HCT116 cells were transfected with empty vector or Flag and Myc-tagged PRAS40 wild-type (WT), the PRAS40 mutants 
S183D and T246D, or the double mutant S183D/T246D for 48 hours. The cell lysates were immunoprecipitated with the anti-Flag antibody 
followed by Western blot analysis for the indicated proteins. D. Inhibition of cap-dependent translation activity in MCF7 and HCT116 cells 
transfected with the Flag and Myc-tagged PRAS40 WT, the PRAS40 mutants S183D and T246D, or the double mutant S183D/T246D, was 
determined and analyzed as in Figure 1C. Data shown in graphs represent the mean ± S.E.M. (n = 3). *P < 0.02 for PRAS40 S183D/T246D 
versus PRAS40 WT, PRAS40 S183D or PRAS40 T246D. 
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and that 4E-BP1 integrates the effects of AKT and 
mTORC1 activation on cap-dependent translation, cell 
proliferation, survival and motility in tumor cells with 
mutational activation of the PI3K/AKT signaling pathway.
Phosphorylation of PRAS40 is a key effector of 
translational activation by AKT and mTORC1 
signaling for cell proliferation, survival and 
motility
PRAS40 is a negative regulator of mTORC1 
activity by competing with p70S6K and 4E-BP1 for 
binding to raptor [16, 18]. However, post-translational 
phosphorylation can inhibit the PRAS40 activity. AKT 
phosphorylates PRAS40 on Thr246 [15], whereas 
mTORC1 phosphorylates PRAS40 on Ser183 [18]. When 
phosphorylated, PRAS40 binding to raptor is reduced, so 
its ability to inhibit mTORC1 is affected as well [16, 18]. In 
a panel of cancer cell lines, shown in Figure 1A, inhibition 
of AKT with MK2206 clearly inhibited phosphorylation 
of PRAS40 at Thr246, whereas inhibition of mTORC1 
with rapamycin did not affect the Thr246 phosphorylation 
(Figure 4A). However, this phosphorylation showed more 
inhibition with rapamycin in combination with MK2206 
than with MK2206 alone. Similarly, combined treatment 
with rapamycin and MK2206 was required to inhibit 
phosphorylation of PRAS40 at Ser183 in a significant 
manner, whereas inhibition with either agent alone caused 
only modest or no effect. As such, the combination of 
rapamycin and MK2206 induced a greater level PRAS40 
binding to raptor than did either agent alone in HCT116 
cells (Figure 4B). 
To establish that effective inhibition of PRAS40 
activity requires both mTORC1 and AKT signaling 
for PRAS40 phosphorylation, we generated PRAS40 
phosphorylation-mimicking mutants in which Ser183 
and/or Thr246 phosphorylation sites were replaced 
with aspartic acids. We transfected wild-type PRAS40, 
the PRAS40 mutants S183D and T246D, or the double 
mutants S183D/T246D into MCF7 and HCT116 cells 
(Figure 4C, 4D). As compared to wild-type PRAS40, the 
S183D mutant exhibited a marked reduction in its ability 
to bind to raptor and mTOR, whereas the binding with the 
T246D mutant resembled that of the wild type. However, 
the greatest reduction in PRAS40 bound to the raptor/
mTOR complex occurred with the double mutant (Figure 
4C). In addition, the degree of PRAS40 mutant binding to 
the raptor/mTOR complex correlated with the extent of 
inhibition of cap-dependent translation (Figure 4D). The 
double mutant significantly attenuated the inhibitory effect 
on cap-dependent translation more than that induced by 
either S183D or T246D.
Disabling the inhibitory effects of PRAS40 by 
phosphorylation may exert important biologic effects in 
transformed cells. Knockdown of PRAS40 expression 
with two different sets of shRNAs in MCF7 and HCT116 
cells upregulated phosphorylation of 4E-BP1, p70S6K 
and S6 (Figure 5A) and enhanced cap-dependent 
translation activity (Figure 5B), suggesting that mTORC1 
was activated by PRAS40 knockdown. Furthermore, 
silencing PRAS40 expression in these two cell lines also 
promoted cell growth (Figure 5C), and exhibited a two- 
to five-fold increase in cell migration and invasion as 
compared with the control cells (Figure 5D, 5E and 5F). In 
addition, BT474 cells with stable knockdown of PRAS40 
expression provided similar results (Figure 5D, 5E). 
Our data suggest that in cancer cells, AKT and 
mTORC1 cooperate to maintain phosphorylation of 
PRAS40, which in turn, relieves PRAS40-inhibitory 
constraint on mTORC1 activity; the activated mTORC1 
supports cap-dependent translation by phosphorylation of 
4E-BP1 and promotes cell growth and motility. To confirm 
this assertion, we examined the effects of AKT and 
mTORC1 inhibitors, alone and in combination, in control 
and PRAS40 knockdown MCF7 and HCT116 cells (Figure 
6). Rapamycin alone effectively inhibited phosphorylation 
of p70S6K and S6 in both control and PRAS40 
knockdown cells (Figure 6A). In contrast, treatment with 
the combination of rapamycin and MK2206 was required 
for effective inhibition of 4E-BP1 phosphorylation and 
cap-dependent translation in control cells (Figure 6A, 6B). 
However, knockdown of PRAS40 expression markedly 
reversed the inhibitory effects seen with the combination 
treatment. Similar to findings obtained with knockdown of 
4E-BP1 expression (Figures 2 and 3), silencing PRAS40 
expression abrogated G1 arrest, induction of apoptosis 
and inhibition of cell migration induced by combined 
treatment with rapamycin and MK2206 when compared 
with results obtained in control cells (Figure 6C, 6D 
and 6E). Collectively, these data indicate that PRAS40 
integrates the effects of AKT and mTORC1 activation 
on 4E-BP1-mediated translational regulation of cell 
proliferation, survival and motility.
AKT inhibition enhances the antitumor activity of 
rapamycin in vivo
The profound anti-proliferative and apoptotic effects 
of the combination of AKT and mTORC1 inhibitors 
in vitro suggest that targeting both AKT and mTORC1 
signaling may be a rational strategy for the treatment of 
tumors with PIK3CA mutation. To explore the feasibility 
of this therapeutic strategy, we tested the safety and 
efficacy of inhibiting mTORC1 and AKT in PIK3CA 
mutant MCF7 tumor xenografts in vivo. As we and others 
have previously shown, the AKT inhibitor MK2206 at 100 
mg/kg and the mTORC1 inhibitor rapamycin at 4 mg/kg 
effectively inhibit the phosphorylation of AKT and S6, 
respectively, in PIK3CA or PTEN mutant xenografts [26, 
31, 32]. Nude mice bearing established MCF7 xenografts 
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Figure 5: Silencing PRAS40 expression upregulates mTORC1 activity and promotes cell growth and motility. A. Cell 
lysates were prepared from MCF7 and HCT116 cells with stable expression of control shRNA or two different sets of PRAS40 shRNAs, 
Western blot analysis was used to detect the indicated proteins. B. Cap-dependent translation activity in MCF7 and HCT116 cells with 
stable expression of control shRNA or PRAS40 shRNA was determined and analyzed as in Figure 1C. C. Cell proliferation analysis 
was performed in MCF7 and HCT116 cells with stable expression of control shRNA or PRAS40 shRNA. D, E. Migration analysis was 
performed in the indicated cell lines with stable expression of control shRNA or PRAS40 shRNA. The results are expressed as the fold 
change of cell migration in Sh PRAS40 cells relative to the Sh Ctrl cells. Scale bar = 500 µm. F. Invasion analysis of HCT116 cells with 
stable expression of control shRNA or PRAS40 shRNA was performed as in Figure 3B. Data shown in graphs represent the mean ± S.E.M. 
(n = 3). *P < 0.02 for Sh PRAS40 versus Sh Ctrl.
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were treated with rapamycin (5 times/week at 4 mg/kg), 
MK2206 (3 times/week at 100 mg/kg), a combination of 
both drugs, or vehicle control for 3 weeks. Administration 
of rapamycin or MK2206 alone slowed growth of tumors, 
but they still grew significantly. In contrast, treatment 
with both drugs led to a complete suppression of tumor 
growth, along with modest tumor regression (Figure 7A, 
7B). In addition, chronic administration of both drugs at 
the indicated dose and schedule was well tolerated with 
no weight loss in the animals (Supplementary Figure 
4). Western blot analysis of tumor extracts revealed that 
rapamycin potently repressed phosphorylation of p70S6K 
and S6, but induced feedback activation of AKT (Figure 
7C). MK2206 effectively inhibited AKT phosphorylation, 
but had no effect on the levels of phosphorylation of 
p70S6K and S6 (Figure 7C), which was different from 
what we observed in vitro (Figure 1A). The reason for 
this inconsistency is not clear but may be due to mTOR 
activation independent of AKT by 17β-estradiol [33] 
that was used for the maintenance of estrogen-dependent 
MCF7 xenograft tumor growth in vivo. Nevertheless, 
neither rapamycin nor MK2206 alone inhibited 
phosphorylation of PRAS40 and 4E-BP1 effectively, and 
neither drug alone induced significant PARP cleavage. In 
contrast, treatment with both drugs resulted in a dramatic 
inhibition of PRAS40 and 4E-BP1 phosphorylation and 
increase in PARP cleavage. These data highlight the 
effectiveness of concomitant inhibition of mTORC1 and 
AKT. 
Figure 6: PRAS40 integrates the effects of AKT and mTORC1 signaling on 4E-BP1-regulated translation, cell 
proliferation, survival and motility. A. MCF7 cells with stable expression of control shRNA or PRAS40 shRNA were treated with 
50 nM rapamycin (Rap) and 1 µM MK2206, alone or in combination, or DMSO as control for 12 h. Cell lysates were subjected to Western 
blot analysis for the indicated proteins. B. Inhibition of cap-dependent translation activity by the indicated drugs in MCF7 and HCT116 
cells with stable expression of control shRNA or PRAS40 shRNA, was determined and analyzed as in Figure 1C. C, D. The increased 
levels of G1 C. and apoptosis D. by the indicated drugs in MCF7 cells with stable expression of control shRNA or PRAS40 shRNA, were 
determined as in Figure 2B and 2C, respectively. E. Inhibition of migration by the indicated drugs in MCF7 cells with stable expression of 
control shRNA or PRAS40 shRNA, was determined and analyzed as in Figure 3C. Data shown in graphs represent the mean ± S.E.M. (n = 
3). *P < 0.02 for combination of Rap and MK2206 in Sh PRAS40 cells versus that in Sh Ctrl cells.
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DISCUSSION
A number of studies have shown that rapamycin 
and rapalogs induce feedback activation of AKT and 
the combination of rapamycin (or rapalogs) and AKT 
inhibitors results in additive or synergistic antitumor 
effects [34-38]. However, the molecular mechanism 
underlying the biological significance of the crosstalk 
between mTORC1 and AKT signaling during malignant 
transformation and therapeutic response to AKT/mTOR 
inhibitors has remained largely undetermined. In this 
study, we provide evidence to demonstrate that the 
convergent phosphorylation of PRAS40 (or inhibition 
of PRAS40 function) by activated AKT and mTORC1 
signaling plays a crucial role in maintaining a transformed 
phenotype through 4E-BP1-regulated translation. This 
concept is supported by the following findings: (i) 
inhibition of either mTORC1 by rapamycin or AKT by 
MK2206 is insufficient to inhibit phosphorylation of 4E-
BP1 and cap-dependent translation (Figure 1), which 
is associated with incomplete inhibition of PRAS40 
phosphorylation on both Ser183 and Thr246 sites (Figure 
4); (ii) inhibition of both mTORC1 and AKT is required 
for effective dephosphorylation of PRAS40 at these 
two sites, thereby enhancing the ability of PRAS40 to 
inhibit mTORC1-mediated 4E-BP1 phosphorylation and 
cap-dependent translation concomitant with profound 
suppression of cell proliferation, survival and motility as 
well as tumor growth; and (iii) knockdown of PRAS40 
Figure 7: Combined inhibition of AKT and mTORC1 is required to dephosphorylate PRAS40 and 4E-BP1 and 
suppress tumor growth in vivo. A, B. Mice bearing MCF7 xenograft tumors were treated with rapamycin (Rap) (4 mg/kg five times/
week), MK2206 (100 mg/kg three times/week), combination of both drugs, or vehicle control, and tumor size was measured by caliper 
two times per week. The results are presented as the mean tumor volume ± S.E.M. (n = 5 mice/group). *P < 0.05; **P < 0.02; ***P < 
0.01 for combination of Rap and MK2206 versus Rap, MK2206 or vehicle control. C. Representative tumors from mice in A. were lysed 
6 h after the final treatment with the indicated drugs. Tumor lysates were subjected to Western blot analysis for the indicated proteins. 
D. A proposed model to illustrate the role of PRAS40 in integrating the effects of AKT and mTORC1 signaling on 4E-BP1-mediated 
translational regulation of tumor growth and therapeutic response to AKT/mTOR inhibitors. RTK, receptor tyrosine kinase.
Oncotarget13972www.impactjournals.com/oncotarget
or 4E-BP1 markedly rescues these inhibitory effects 
induced by combined inhibition of mTORC1 and AKT. 
Our findings reveal a novel PRAS40/4E-BP1 axis at the 
crossroads of AKT and mTORC1 signaling and present 
a potential avenue for therapeutic control of cancer 
progression (Figure 7D).
The p70S6K is another well-known substrate of 
mTORC1. Although p70S6K and its substrate ribosomal 
protein S6 are also known as regulators of mRNA 
biogenesis and translation, a growing body of evidence, 
including our studies, indicate that the deregulation of cap-
dependent translation downstream of mTORC1 at the level 
of 4E-BP1/eIF4E plays a central role in tumor formation 
and metastatic progression; the contribution of p70S6K1 
and S6 to the oncogenic action of the mTORC1 upstream 
activators, AKT and/or extracellular signal-regulated 
kinase, appears limited [12, 27, 39, 40]. Consistent with 
previous studies [11, 12, 27, 39, 41], our findings support 
the notion that the phosphorylation status of S6 may not 
be a relevant biomarker to predict treatment efficacy for 
mTORC1 inhibitors, because loss of S6 phosphorylation 
by rapamycin does not always correlate with inhibition 
of all mTORC1 substrates such as 4E-BP1 and PRAS40. 
It remains largely unknown why mTORC1 
substrates show differential sensitivities to rapamycin 
in cancer cells. The molecular nature of rapamycin as 
an mTORC1 inhibitor differs from the ATP-competitive 
kinase inhibitors in that it forms a complex with FKBP12 
and inhibits the ability of mTORC1 to phosphorylate 
its substrates through an unknown mechanism [22]. A 
recent report by Kang et al. suggests that the sequence 
composition of an mTORC1 phosphorylation site is one 
of the key determinants of whether the site is good or poor 
mTORC1 substrate within cells [42]. In this report, they 
found that mTORC1 could strongly phosphorylate 4E-BP1 
on both Thr37 and Thr46 sites, so that even the reduced 
activity of rapamycin-bound mTORC1 would be sufficient 
to keep them phosphorylated. In other words, inhibition of 
mTORC1 activity by rapamycin is insufficient to inhibit 
4E-BP1 phosphorylation, thereby resulting in it resistance 
to rapamycin. In contrast, they showed that mTORC1 
weakly phosphorylates p70S6K on Thr389, which is 
rapamycin sensitive as the reduction of mTORC1 activity 
by rapamycin is sufficient to inhibit its phosphorylation. 
These findings suggest that maximal inhibition of 
mTORC1 activity is required for effective suppression 
of phosphorylation of rapamycin-resistant mTORC1 
substrates. Interestingly, we found that inhibition of AKT 
activity markedly enhances the ability of rapamycin to 
inhibit phosphorylation of 4E-BP1 both in vitro and in 
vivo. Our data suggest that AKT inhibition can reverse 
rapamycin-resistant mTORC1 substrates being sensitive 
to rapamycin. Mechanistically, we found that this reversal 
is likely due to a more complete dephosphorylation of 
PRAS40, which leads to an increase in the formation 
of PRAS40-raptor complex by enhancing inhibition of 
mTORC1 activity for phosphorylation of 4E-BP1. We 
demonstrated that a combination of AKT and mTORC1 
inhibitors is required to effectively inhibit phosphorylation 
of PRAS40 on both Ser183 and Thr246 sites and increases 
PRAS40 binding to raptor (Figure 4A, 4B). Conversely, 
phosphorylation of both Ser183 and Thr246 is required 
to reduce PRAS40 binding to raptor/mTOR complex and 
attenuate the inhibitory effect of PRAS40 on mTORC1/4E-
BP1-mediated cap-dependent translation (Figure 4C, 4D). 
In addition, given that PRAS40 competes with p70S6K 
and 4E-BP1 for binding to raptor and inhibiting mTORC1 
activity on its substrates [16, 18], the alterations in the 
molecular interaction among p70S6K, 4E-BP1, PRAS40, 
raptor, mTOR and rapamycin may yield scenarios where 
the ability of the substrate binding to raptor/mTOR and the 
sensitivity to rapamycin-induced disassociation may differ. 
Whether the increase of PRAS40 bound to raptor by the 
combination of rapamycin and AKT inhibition is required 
for the dissociation of 4E-BP1 rather than p70S6K from 
raptor remains to be determined.
It is important to note that prolonged treatment with 
rapamycin has been shown to inhibit AKT via disruption 
of mTORC2 assembly in certain cell lines [43], but in 
many other cell types including preclinical and clinical 
specimens in our present and prior studies as well as others 
reports, chronic administration of rapamycin could induce 
substantial activation of AKT signaling [22, 24, 25, 34-38, 
43, 44]. In addition to the PIK3CA mutant tumor cells as 
we tested in this study, we and others also observed that in 
KRAS mutant and wild-type colon and lung cancer cells, 
rapamycin could also elicit AKT activation and increase 
the level of AKT-mediated phosphorylation of PRAS40 
on Thr246 (Supplementary Figure 5) [38]. Moreover, 
combined inhibition of AKT and mTORC1 is also required 
to effectively inhibit phosphorylation of both PRAS40 and 
4E-BP1 and cell growth in these cells (Supplementary 
Figure 5) [38]. These data suggest that co-targeting AKT 
and mTORC1 signaling may be a useful therapeutic 
strategy for many malignancies. However, a detailed 
analysis of different tumors with specific genotypes is 
needed to determine the role of PRAS40/mTORC1/4E-
BP1 axis in the effectiveness and therapeutic index of this 
approach. 
The implications of our findings suggest that the 
ATP-competitive mTOR kinase inhibitors (mTORKIs) that 
inhibit both mTORC1 and mTORC2 may provide better 
therapeutic outcomes when compared with rapamycin in 
the clinic. mTORC2 directly phosphorylates AKT at its 
hydrophobic motif (Ser473), which enhances the catalytic 
activity of AKT already phosphorylated on Thr308 [45]. 
In contrast to rapamycin-induced feedback activation 
of AKT with limited inhibitory activity on 4E-BP1 
phosphorylation, the mTORKIs can effectively inhibit 
AKT phosphorylation on Ser473 and show much greater 
repression on 4E-BP1 phosphorylation [46, 47]. However, 
a recent report by Rodrik-Outmezguine et al. showed that 
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phosphorylation of AKT at the Thr308 site and of the AKT 
substrates including PRAS40, GSK-3β and FOXO1/3 
are only transiently repressed by mTORKIs in PIK3CA 
mutant (MCF7, BT474) and PTEN-deficient (MDA-
MB-468) breast cancer cell lines [48]. Moreover, the 
mTORC1-mediated phosphorylation of 4E-BP1 on Thr37/
Thr46 also rebounded between 8 and 24 h after treatment 
with mTORKIs such as AZD8055 and PP242. They 
found that inhibition of mTOR kinase relieves feedback 
inhibition of receptor tyrosine kinases, which causes 
subsequent activation of PI3K and re-phosphorylation 
of AKT on Thr308 sufficient to reactivate AKT activity 
and signaling, whereas combination of mTORKIs and 
AKT inhibitors demonstrates a more stable inhibition 
of 4E-BP1 phosphorylation than mTORKIs alone and 
dramatically induces apoptosis [48]. Consistent with 
these findings, our recent study also showed that although 
knockdown of raptor expression markedly inhibits 4E-
BP1 phosphorylation, inhibition of AKT activity could 
further attenuate 4E-BP1 phosphorylation associated with 
significant antitumor effects in raptor-knockdown colon 
cancer cells [9]. Furthermore, additional experimental 
evidence has highlighted that incomplete inhibition of 4E-
BP1 phosphorylation is a mechanism of primary resistance 
to mTORKIs [13, 49]. These studies identified that 
KRAS-mutant SW620 colon cancer cells are particularly 
resistant to PP242, and PP242 cannot effectively inhibit 
4E-BP1 phosphorylation. Intriguingly, we found that AKT 
inhibition by MK2206 in combination with PP242 could 
elicit more profound inhibition of 4E-BP1 phosphorylation 
compared to the responses to PP242 alone (Supplementary 
Figure 6). Taken together, these data suggest that AKT 
kinase may be involved in the regulation of 4E-BP1 
phosphorylation and translation in mTORC1-depedent 
and -independent manners, and that combined inhibition 
of mTOR and PI3K/AKT may be a promising therapeutic 
strategy for many malignancies. Indeed, dual inhibition 
of PI3K and mTORC1/2 signaling by NVP-BEZ235 or 
rapalogs in combination with PI3K or AKT inhibitors has 
demonstrated profound efficacy in a variety of preclinical 
models of cancers [34-37, 50-56]. 
In summary, our study provides new insight into 
the biologic and therapeutic relevance of PRAS40 in 
translational regulation of tumor cell proliferation, 
survival and motility. Our findings reveal that regulation 
of PRAS40 activity through cooperative AKT and 
mTORC1 phosphorylation of both Ser183 and Thr246 
is a key process to alter the mTORC1 substrate (e.g. 4E-
BP1) specificity. In addition to the phosphorylation of 
4E-BP1, PRAS40 phosphorylation may also serve as a 
surrogate marker to evaluate the response to the PI3K/
AKT/mTOR pathway inhibitors in clinic. These findings 
could have high translational significance and enhance our 
understanding of the involvement of PRAS40 and 4E-BP1 
in the regulation of cancer progression and therapeutics.
MATERIALS AND METHODS
Cell culture, inhibitors, constructs, and lentiviral 
shRNA silencing
Human breast and colon cancer cell lines were 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA) and maintained in the appropriate 
medium with supplements as suggested by ATCC. 
Rapamycin and MK2206 were obtained from LC 
Laboratories (Woburn, MA) and Selleck (Houston, TX), 
respectively. The PRK5-PRAS40 construct was from 
Addgene (Cambridge, MA). The PRAS40 cDNA was 
amplified by PCR using PRK5-PRAS40 as a template and 
the product subcloned into the Sgf I and Mlu I sites of 
pCMV6-Myc-Flag (Origene, Rockville, MD). The insert 
was mutated using a QuikChange XLII mutagenesis 
kit (Stratagene, Santa Clara, CA). Mutants with Asp at 
Ser183 (S183D), Thr246 (T246D) and both Ser183 and 
Thr246 (S183D/T246D) were generated in pCMV6-Myc-
Flag. All constructs were verified by DNA sequencing. 
Lentiviral shRNAs to human 4E-BP1 were from Open 
Biosystems (Lafayette, CO) and the specificity of the 
targeting sequences has been verified in our previous 
study [9]. Lentiviral shRNAs to human PRAS40 and the 
Non-Target Control shRNA (SHC002) were from Sigma 
(St Louis, MO). The accession numbers of PRAS40 
ShRNA_1 and PRAS40 ShRNA_2 are TRCN0000158835 
and TRCN00001666394, respectively. For establishing 
stable transfectants with knockdown of specific protein 
expression, cell lines were lentivirally infected with the 
indicated shRNA construct followed by selection with 
puromycin (2 µg/ml) for one week as described previously 
[9].
Cell proliferation assay
Cell proliferation was assessed by counting the 
number of viable cells in response to the treatment with 
the indicated drugs as described previously [9].
Cell-cycle analysis and apoptosis assay
Cells were plated in 100-mm dishes, grown 
overnight, and treated as indicated in figure legends. Both 
adherent and floating cells were harvested. For cell-cycle 
analysis, cell nuclei were prepared by the method of Nusse 
[57] and stained with ethidium bromide as described [26]. 
Cell cycle distribution was determined by flow cytometry. 
For apoptosis, cells were analyzed by flow cytometry 
using the Annexin V-FITC Apoptosis Detection Kit 
according to the manufacturer’s protocol (BD Biosciences, 
San Jose, CA, USA).
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Migration and invasion assays
Migration and invasion assays were performed 
in Boyden chambers with coated collagen or Matrigel, 
respectively, as instructed by the manufacturer (BD 
Biosciences) and described previously [9]. 
Western blot analysis
Cells were lysed in NP-40 lysis buffer, and analyzed 
by Western blot using equal total protein loading as 
described previously [12]. Phosphorylation-specific 
antibodies and antibodies for PRAS40, 4E-BP1, eIF4E, 
raptor, Myc tag, cleaved PARP, cleaved caspase-3 and 
caspase-7 were from Cell Signaling Technology (Danvers, 
MA). mTOR antibody (H-266) was from Santa Cruz 
Biotechnology (Dallas, TX) and β-actin antibody was 
from Sigma.
Immunoprecipitation
PRAS40 complexes were immunoprecipitated 
with PRAS40 antibody (Clone 73P21, EMD Millipore, 
Billerica, MA) or anti-Flag antibody (Sigma) according to 
the procedure described by Sancak et al [16]. At the end, 
the immunoprecipitates from 0.5 to 1 mg protein of cell 
lysates captured with protein G Sepharose were analyzed 
by Western blot. 
Cap-binding assay
Cell lysates as prepared above were incubated with 
m7GTP Sepharose beads (GE Healthcare Bio-Sciences, 
Pittsburgh, PA) to capture eIF4E and its binding partners. 
Precipitates were washed three times with lysis buffer and 
resuspended in 2× Laemmli sample buffer followed by 
Western blot analysis. 
Quantification of cap-dependent translation 
activity
Cells (80,000) were transfected with a bicistronic 
luciferase reporter plasmid (0.2 µg), pcDNA3-rLuc-
PolioIRES-fLuc, which directs cap-dependent translation 
of the Renilla luciferase gene and cap-independent Polio 
IRES-mediated translation of the firefly luciferase gene 
[58], in 12-well plates using X-tremeGENE Transfection 
Reagent (Roche Applied Science, Indianapolis, IN). After 
24 h transfection, cells were treated with kinase inhibitors 
for the indicated times, and cell lysates were assayed 
for renilla luciferase and firefly luciferase activities as 
described [9, 12]. Cap-dependent renilla activity was 
normalized against cap-independent firefly activity as the 
internal control. The renilla/firefly luciferase luminescence 
ratio was calculated for cap-dependent translational 
activity.
Animal studies
Female athymic nude mice (5-6 weeks old) were 
purchased from Taconic (Hudson, NY). Experiments 
were carried out under a protocol approved by the 
University of Kentucky Institutional Animal Care and 
Use Committee. MCF7 xenograft tumors were established 
by subcutaneously implanting 0.72 mg sustained release 
17β-estradiol pellets into one flank at least 3 days before 
injecting 5 × 106 cells suspended 1:1 (volume) with growth 
factor-reduced Matrigel (BD Biosciences) on the opposite 
side. For efficacy studies, mice were randomized among 
control and treated groups (n = 5 per group) when tumors 
were well-established (~150-180 mm3). Rapamycin was 
prepared in absolute ethanol at 10 mg/ml and diluted 
in 5% Tween-80 and 5% PEG-400 before injection. 
Rapamycin was administered by intraperitoneal injection 
at 4 mg/kg once per day, Mon-Fri as previously reported 
[32]. MK2206 was formulated in 30% captisol and given 
orally at 100 mg/kg once per day, Mon-Wed-Fri based 
on previous reports [31]. Control mice received a vehicle 
solution. Tumor dimensions were measured using a caliper 
and tumor volumes were calculated as mm3 = π/6 x larger 
diameter x (smaller diameter)2. Tumors were excised and 
snap frozen in liquid nitrogen, homogenized in 2% SDS 
lysis buffer and then processed for Western blot analysis 
as described previously [9, 12].
Statistical analysis
All experiments were performed at least twice. 
Results are expressed as mean ± S.E.M. where applicable. 
A two-tailed Student’s t-test was used to compare the 
intergroup. Differences between groups were considered 
statistically significant at P < 0.05.
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